Literature DB >> 33091330

The Ki-67 proliferation index predicts recurrence-free survival in patients with dermatofibrosarcoma protuberans.

Deligonul Adem1, Serkan Yazici2, Mine Ozsen3, Sibel Kahraman Cetintas4, Ulviye Yalcinkaya3, Ahmet Bilgehan Şahin1, Ozgur Tanrıverdi5, Sibel Oyucu Orhan1, Birol Ocak1, Erdem Cubukcu1, Ramazan Kahveci6, Turkkan Evrensel1.   

Abstract

Dermatofibrosarcoma protuberans (DFSP) is an uncommon soft tissue sarcoma that originates from the dermis or subcutaneous tissue in the skin. While its prognosis is generally favorable, disease recurrence is relatively frequent. Because morbidity after repeated surgery may be significant, an optimized prediction of recurrence-free survival (RFS) has the potential to improve current management strategies. The purpose of this study was to investigate the prognostic value of the Ki-67 proliferation index with respect to RFS in patients with DFSP. We retrospectively analyzed data from 45 patients with DFSP. We calculated the Ki-67 proliferation index as the percentage of immunostained nuclei among the total number of tumor cell nuclei regardless of the intensity of immunostaining. We constructed univariate and multivariate Cox proportional hazards regression models to identify predictors of RFS. Among the 45 patients included in the study, 8 developed local recurrences and 2 had lung metastases (median follow-up: 95.0 months; range: 5.2-412.4 months). The RFS rates at 60, 120, and 240 months of follow-up were 83.8%, 76.2%, and 65.3%, respectively. The median Ki-67 proliferation index was 14%. Notably, we identified the Ki-67 proliferation index as the only independent predictor for RFS in multivariate Cox proportional hazards regression analysis (hazard ratio = 1.106, 95% confidence interval = 1.019-1.200, p = 0.016). In summary, our results highlight the potential usefulness of the Ki-67 proliferation index for facilitating the identification of patients with DFSP at higher risk of developing disease recurrences.

Entities:  

Year:  2021        PMID: 33091330      PMCID: PMC7982062          DOI: 10.17305/bjbms.2020.5088

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  17 in total

Review 1.  Ki67 is a promising molecular target in the diagnosis of cancer (review).

Authors:  Lian Tao Li; Guan Jiang; Qian Chen; Jun Nian Zheng
Journal:  Mol Med Rep       Date:  2014-11-10       Impact factor: 2.952

2.  Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy.

Authors:  Ryan C Fields; Meera Hameed; Li-Xuan Qin; Nicole Moraco; Xiaoyu Jia; Robert G Maki; Samuel Singer; Murray F Brennan
Journal:  Ann Surg Oncol       Date:  2010-09-16       Impact factor: 5.344

3.  Phosphohistone-H3 and Ki67: Useful Markers in Differentiating Dermatofibroma From Dermatofibrosarcoma Protuberans and Atypical Fibrohistiocytic Lesions.

Authors:  Atin Agarwal; Arun Gopinath; Michael T Tetzlaff; Victor G Prieto
Journal:  Am J Dermatopathol       Date:  2017-07       Impact factor: 1.533

Review 4.  Dermatofibrosarcoma Protuberans.

Authors:  Alvaro E Acosta; Catalina Santa Vélez
Journal:  Curr Treat Options Oncol       Date:  2017-08-10

Review 5.  Current Update on the Molecular Biology of Cutaneous Sarcoma: Dermatofibrosarcoma Protuberans.

Authors:  Takeshi Iwasaki; Hidetaka Yamamoto; Yoshinao Oda
Journal:  Curr Treat Options Oncol       Date:  2019-03-14

Review 6.  Dermatofibrosarcoma protuberans: pathology, genetics, and potential therapeutic strategies.

Authors:  Khin Thway; Jonathan Noujaim; Robin L Jones; Cyril Fisher
Journal:  Ann Diagn Pathol       Date:  2016-09-27       Impact factor: 2.090

7.  Incidence and Survival of Primary Dermatofibrosarcoma Protuberans in the United States.

Authors:  Kathryn L Kreicher; David E Kurlander; Haley R Gittleman; Jill S Barnholtz-Sloan; Jeremy S Bordeaux
Journal:  Dermatol Surg       Date:  2016-01       Impact factor: 3.398

Review 8.  Ki67 targeted strategies for cancer therapy.

Authors:  C Yang; J Zhang; M Ding; K Xu; L Li; L Mao; J Zheng
Journal:  Clin Transl Oncol       Date:  2017-10-20       Impact factor: 3.340

9.  Dermatofibrosarcoma protuberans: a study of clinical, pathologic, genetic, and therapeutic features in Korean patients.

Authors:  Zhenlong Zheng; Junjei Piao; Ji-Hye Lee; Song-Ee Kim; Soo-Chan Kim; Kee Yang Chung; Mi Ryung Roh
Journal:  Yonsei Med J       Date:  2015-03       Impact factor: 2.759

10.  Role of postoperative radiotherapy in dermatofibrosarcoma protuberans: a propensity score-matched analysis.

Authors:  Kaixin Du; Jinluan Li; Lirui Tang; Xiaoyi Lin; Xiangquan Kong; Xuehong Liao; Qingqin Peng; Yaping Dong; Junyan He; Yunxia Huang; Xueqing Zhang; Feifei Lin; Qingyang Zhuang; Junxin Wu
Journal:  Radiat Oncol       Date:  2019-01-29       Impact factor: 3.481

View more
  1 in total

1.  Development and validation of nomograms for predicting survival of elderly patients with stage I small-cell lung cancer.

Authors:  Yaji Yang; Shusen Sun; Yuwei Wang; Feng Xiong; Yin Xiao; Jing Huang
Journal:  Bosn J Basic Med Sci       Date:  2021-10-01       Impact factor: 3.363

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.